

Supplementary Table 2. Univariate analysis of factors associated with post-recurrence survival

Factor	HR (95% CI)	P-value
Age (yr)		0.566
≥50	1	
<50	0.81 (0.39-1.66)	
FIGO stage		0.271
Early stage	1	
Advanced stage	1.55 (0.72-3.32)	
Primary treatment		0.817
Neoadjuvant therapy	1	
Primary surgery	0.8 (0.11-5.92)	
Surgical outcome		0.71
Optimal surgery	1	
Sub-optimal surgery	1.21 (0.46-3.19)	
Ascites cytology		0.708
Negative	1	
Positive	1.39 (0.64-3.03)	
LVSI		0.398
Negative	1	
Positive	1.02 (0.35-2.94)	
CA 125 (IU/mL)		0.359
<35	1	
≥35	1.54 (0.59-4.05)	
Site of recurrence		0.039
Single-site	1	
Multiple	2.74 (1.15-6.51)	
Nodal	0.96 (0.16-7.89)	
Tumor free interval ^{a)}		0.383
≥12 months	1	
<12 months	0.72 (0.35-1.49)	
Post-recurrence treatment		0.40
Surgery	1	
Radiotherapy	0.98 (0.09-11.27)	
Chemotherapy	0.78 (0.1-5.94)	
Combined treatment	0.27 (0.02-3.19)	

HR, hazard ratio; CI, confidence interval; FIGO stage, International Federation of Gynecology and Obstetrics stage 2014; LVSI, lympho-vascular space invasion; CA 125, cancer antigen 125.

^{a)}Tumor free interval means time from date of complete treatment to date of first recurrence of disease.